Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Dose Escalation and Expansion Trial to Evaluate the Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

NCT07463599 is registered in ClinicalTrials.gov with HonorHealth Research Institute as lead sponsor.

NCT NCT07463599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07463599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Dose Escalation and Expansion Trial to Evaluate the Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Lead sponsor
HonorHealth Research Institute
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 17, 2026
Completion date
July 31, 2029
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenomatous polyposis coli (apc) gene mutation, catenin beta-1 (ctnnb1) gene mutation, colorectal cancer (crc), metastatic colorectal carcinoma (mcrc)